Kalinkov D, Buchholz R
Am J Obstet Gynecol. 1980 Dec 15;138(8):1148-50. doi: 10.1016/s0002-9378(16)32782-x.
The aim of this study was to correlate the relationship between serum cystine aminopeptidase (CAP) activity in normal patients and that in patients with primary ovarian cancer of recurrence. Sera obtained from 63 patients and evaluated for CAP activity by the method of Babuna and Yenen were grouped as follows: in 20 normal, nonpregnant patients, the mean activity was 25; in 14 patients with fibromas of the uterus, it was 38; in two patients with ovarian sarcoma, the activities were "normal" (24 to 27); and in 27 patients with primary ovarian adenocarcinoma or recurrence, the activity corresponded to the size of the tumors. Assay of serum CAP activity is a simple procedure which can be performed in any laboratory. It is a quick method for qualitative, and even quantitative, assessment of an ovarian adenocarcinoma in the nonpregnant patient. It may prove to be especially valuable in the follow-up of patients with ovarian cancer.
本研究的目的是关联正常患者与原发性复发性卵巢癌患者血清胱氨酸氨基肽酶(CAP)活性之间的关系。从63例患者中获取血清,并采用巴布纳(Babuna)和耶嫩(Yenen)的方法评估CAP活性,分组如下:20例正常非妊娠患者的平均活性为25;14例子宫纤维瘤患者的活性为38;2例卵巢肉瘤患者的活性“正常”(24至27);27例原发性卵巢腺癌或复发性卵巢癌患者的活性与肿瘤大小相关。血清CAP活性检测是一种简单的程序,可在任何实验室进行。它是一种快速评估非妊娠患者卵巢腺癌的定性甚至定量方法。它可能在卵巢癌患者的随访中被证明特别有价值。